Theriva Biologics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Theriva Biologics announced first patient enrollment in VIRAGE2, a Phase 2a single-arm trial with 6 evaluable patients evaluating higher-frequency dosing of VCN-01 combined with standard gemcitabine/nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma. Enrollment expected to complete H2 2026 with initial safety and pharmacodynamic data by Q3 2027. Trial builds on positive VIRAGE Phase 2b data showing improved overall survival with 2-dose VCN-01 regimen and incorporates FDA/EMA feedback on repeated dosing potential.
Why this rating
Clinical milestone materially advances lead asset toward Phase 3 for micro-cap ($3.9M); exploratory dosing refinement critical to regulatory/commercial path, but Phase 2a is small (6 patients) and non-pivotal.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.